Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2015

01-09-2015 | Research Article

Mdig, a lung cancer-associated gene, regulates cell cycle progression through p27KIP1

Authors: Dan Ma, Dan Guo, Wei Li, Hongwen Zhao

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

Mineral dust-induced gene (mdig) can accelerate cell proliferation. The aim of this study is to investigate the mechanism by which mdig regulates cell proliferation. A549 cells were transfected with siRNA specifically targeting mdig. Cell proliferation and cell cycle progression were measured using MTT assay and cell cycle analysis, respectively. Furthermore, real-time reverse transcription quantitative–polymerase chain reaction (RT-qPCR) was performed in A549 cells transfected with mdig siRNA to examine the expression levels of the cell cycle related genes such as p18INK4c, p19INK4d, p21WAF/CIP1, p27KIP1, p57KIP2, cyclin D1, and cyclin E. To further explore the effect of mdig on p27KIP1, the expression levels of total p27KIP1 and its subtypes pT187-p27KIP1 and pS10-p27KIP1 were assessed by Western blotting. In vivo, Western blotting was performed to check the expression levels of mdig and p27KIP1 in human lung cancer tissues, para-cancerous normal lung tissues, and para-bronchial stumps. Knockdown of mdig induced increases in p27KIP1, both on mRNA and protein levels. Furthermore, the phosphorylation of p27KIP1 at its Thr187 site was also inhibited. Importantly, in lung cancer tissues, upregulation of mdig expression accompanies with the downregulation of p27KIP1 expression and in bronchial stump, vice versa. The data suggest that mdig-mediated inhibition of p27KIP1 is important for cell proliferation and tumor formation and reveal therapeutic potential of p27KIP1 for lung cancer.
Literature
1.
de Groot P, Munden RF. Lung cancer epidemiology, risk factors, and prevention. Radiol Clin North Am. 2012;50(5):863–76.CrossRefPubMed
2.
She J, Yang P, Hong Q, Bai C. Lung cancer in China: challenges and interventions. Chest. 2013;143(4):1117–26.CrossRefPubMed
3.
Zhang Y, Yongju L, Yuan B-Z, Castranova V, Shi X, Stauffer JL, et al. The human mineral dust-induced gene, MDIG, is a cell growth regulating gene associated with lung cancer. Oncogene. 2005;24(31):4873–82.CrossRefPubMed
4.
Tsuneoka M, Koda Y, Soejima M, Teye K, Kimura H. A novel myc target gene, mina53, that is involved in cell proliferation. J Biol Chem. 2002;277(38):35450–9.CrossRefPubMed
5.
Yongju L, Chang Q, Zhang Y, Beezhold K, Rojanasakul Y, Zhao H, et al. Lung cancer-associated JmjC domain protein mdig suppresses formation of tri-methyl lysine 9 of histone H3. Cell Cycle. 2009;8(13):2101–9.CrossRef
6.
Tsuneoka M, Fujita H, Arima N, Teye K, Okamura T, Inutsuka H, et al. Mina53 as a potential prognostic factor for esophageal squamous cell carcinoma. Clin Cancer Res. 2004;10(21):7347–56.CrossRefPubMed
7.
Teye K, Tsuneoka M, Arima N, Koda Y, Nakamura Y, Ueta Y, et al. Increased expression of a myc target gene mina53 in human colon cancer. Am J Pathol. 2004;164(1):205–16.CrossRefPubMedPubMedCentral
8.
Ishizaki H, Yano H, Tsuneoka M, Ogasawara S, Akiba J, Nishida N, et al. Overexpression of the myc target gene mina53 in advanced renal cell carcinoma. Pathol Int. 2007;57(10):672–80.CrossRefPubMed
9.
Komiya K, Sueoka-Aragane N, Sato A, Hisatomi T, Sakuragi T, Mitsuoka M, et al. Expression of mina53, a novel c-myc target gene, is a favorable prognostic marker in early stage lung cancer. Lung Cancer. 2010;69(2):232–8.CrossRefPubMed
10.
Miaomiao Y, Sun J, Thakur C, Chen B, Yongju L, Zhao H, et al. Paradoxical roles of mineral dust induced gene on proliferation and migration/invasion. Plos One. 2014;9(2):e87998.CrossRef
11.
Eymin B, Gazzeri S. Role of cell cycle regulators in lung carcinogenesis. Cell Adh Migr. 2009;4(1):114–23.CrossRef
12.
Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle. 2009;8(21):3455–61.CrossRefPubMed
13.
Vincenzi B, Schiavon G, Silletta M, Santini D, Perrone G, Di Marino M, et al. Cell cycle alterations and lung cancer. Histol Histopathol. 2006;21(4):423–35.PubMed
14.
Komiya K, Sueoka-Aragane N, Sato A, Hisatomi T, Sakuragi T, Mitsuoka M, et al. Mina53, a novel c-myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3 T3 cells. J Cancer Res Clin Oncol. 2010;136(3):465–73.CrossRefPubMed
15.
Morgan D. The cell cycle: principles of control. London: New Science Press Ltd; 2007.
16.
MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr. 1995;5(2):127–56.CrossRefPubMed
17.
Esposito V, Baldi A, Tonini G, Vincenzi B, Santini M, Ambrogi V, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol. 2004;57(1):58–63.CrossRefPubMedPubMedCentral
18.
Osada H, Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene. 2002;21(48):7421–34.CrossRefPubMed
19.
Ogasawara S, Komuta M, Nakashima O, Akiba J, Tsuneoka M, Yano H. Accelerated expression of a myc target gene mina53 in aggressive hepatocellular carcinoma. Hepatol Res. 2010;40(4):330–6.CrossRefPubMed
20.
Zhang Q, Hu CM, Yuan YS, He CH, Zhao Q, Liu NZ. Expression of mina53 and its significance in gastric carcinoma. Int J Biol Markers. 2008;23(2):83–8.CrossRefPubMed
21.
Teye K, Arima N, Nakamura Y, Sakamoto K, Sueoka E, Kimura H, et al. Expression of myc target gene mina53 in subtypes of human lymphoma. Oncol Rep. 2007;18(4):841–8.PubMed
22.
Fukahori S, Yano H, Tsuneoka M, Tanaka Y, Yagi M, Kuwano M, et al. Immunohistochemical expressions of Cap43 and mina53 proteins in neuroblastoma. J Pediatr Surg. 2007;42(11):1831–40.CrossRefPubMed
23.
Kuratomi K, Yano H, Tsuneoka M, Sakamoto K, Kusukawa J, Kojiro M. Immunohistochemical expression of mina53 and Ki67 proteins in human primary gingival squamous cell carcinoma. Kurume Med J. 2006;53(3–4):71–8.CrossRefPubMed
24.
Gursky S, Olopade OI, Rowley JD. Identification of a 1.2 Kb cDNA fragment from a region on 9p21 commonly deleted in multiple tumor types. Cancer Genet Cytogenet. 2001;129(2):93–101.CrossRefPubMed
25.
Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, et al. CDK inhibitors p18INK4c and p27Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 1998;12(18):2899–911.CrossRefPubMedPubMedCentral
26.
Slingerland J, Pagano M. Regulation of the CDK inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183(1):10–7.CrossRefPubMed
27.
28.
Medema RH, Kops GJP, Bos JL, Burgering BMT. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27KIP1. Nature. 2000;404(6779):782–7.CrossRefPubMed
29.
Tang L, Wang Y, Strom A, Gustafsson J-A, Guan X. Lapatinib induces p27(KIP1)-dependent G1 arrest through both transcriptional and post-translational mechanisms. Cell Cycle. 2013;12(16):2665–74.CrossRefPubMedPubMedCentral
30.
Ling Y-H, Li T, Yuan Z, Haigentz M, Haigentz Jr M, Weber TK, et al. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung. Mol Pharmacol. 2007;72(2):248–58.CrossRefPubMed
31.
Catzavelos C, Tsao M-S, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. Reduced expression of the cell cycle inhibitor p27KIP1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res. 1999;59(3):684–8.PubMed
32.
Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, et al. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser10 p27 phosphorylation in epidermal growth factor receptor expressing breast cancer. Mol Cancer Ther. 2010;9(11):3090–9.CrossRefPubMedPubMedCentral
33.
Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27KIP1. Genes Dev. 1997;11(11):1464–78.CrossRefPubMed
34.
Park K-H, Seol JY, Kim T-Y, Yoo C-G, Kim YW, Han SK, et al. An adenovirus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type. Cancer Res. 2001;61(16):6163–9.PubMed
35.
Wang D, He F, Zhang L, Zhang F, Wang Q, Qian X, et al. The role of p27KIP1 phosphorylation at serine 10 in the migration of malignant glioma cells in vitro. Neoplasma. 2011;58(1):65–73.PubMed
36.
Kotake Y, Nakayama K, Ishida N, Nakayama KI. Role of serine 10 phosphorylation in p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine 10 mutation. J Biol Chem. 2005;280(2):1095–102.CrossRefPubMed
37.
Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27KIP1 stability, subcellular localization, and tumor suppression. Genes Dev. 2006;20(1):47–64.CrossRefPubMedPubMedCentral
Metadata
Title
Mdig, a lung cancer-associated gene, regulates cell cycle progression through p27KIP1
Authors
Dan Ma
Dan Guo
Wei Li
Hongwen Zhao
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3397-z

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue

Research Article

Role of Lgr5-positive cells in colorectal cancer

Retraction Note

Retraction Note to: Aberrant promoter methylation of the CHD1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis

Research Article

Long non-coding RNA BANCR regulates growth and metastasis and is associated with poor prognosis in retinoblastoma

Research Article

miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma

Research Article

RPF151, a novel capsaicin-like analogue: in vitro studies and in vivo preclinical antitumor evaluation in a breast cancer model

Research Article

Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits